share_log

Clarification on Intellectual Property Matters

Clarification on Intellectual Property Matters

澄清知識產權事宜
Accesswire ·  2022/03/09 08:02

GUELPH, ON / ACCESSWIRE / March 9, 2022 / Zentek Ltd. ("ZEN" or the "Company")(TSX-V:ZEN and OTC PINK:ZENYF), wants to clarify that the technology utilized in its ZenGUARD™ antimicrobial coating was developed exclusively by ZEN at its facility in Guelph, Ontario during the summer of 2020. Zentek's ZenGUARD™ technology does not use any of the technology related to the claim made in the patent applications of Graphene Composites Ltd. ("GC").

Guelph,on/ACCESSWIRE/2022年3月9日/Zentek Ltd. ("禪宗“或”公司(多倫多證券交易所股票代碼:ZEN和OTC PINK:ZENYF)希望澄清,其ZenGUARD™抗菌塗料中使用的技術是Zen於2020年夏天在其位於安大略省圭爾夫的工廠獨家開發的。Zentek的ZenGUARD™技術沒有使用任何與石墨烯複合材料有限公司(“GC”)專利申請中的權利要求相關的技術。

As disclosed March 8, 2022, ZEN received a statement of claim from GC on January 29, 2021, for breach of confidentiality. The Company maintains that this claim is frivolous based on the fact the information shared by GC was already in the public domain. This position is supported by the public examiner's response to Graphene Composites patent application #3,097,636 on April 27, 2021, where the examiner rejected 107 out of 108 claims made by Graphene Composites.

據2022年3月8日披露,Zen於2021年1月29日收到GC的一份違反保密規定的索賠聲明。該公司堅持認為,基於GC共享的信息已經在公共領域內這一事實,這一索賠是無關緊要的。這一立場得到了公共審查員對2021年4月27日#3,097,636號石墨烯複合材料專利申請的迴應的支持,在該申請中,審查員駁回了石墨烯複合材料公司108項權利要求中的107項。

ZEN's patent application will be published on March 21, 2022.

Zen的專利申請將於2022年3月21日公佈。

Greg Fenton, Zentek CEO commented:" Zentek will take every action necessary to protect the reputation of the Company and maximize shareholder value."

Zentek首席執行官格雷格·芬頓評論説:“Zentek將採取一切必要的行動來保護公司的聲譽並使股東價值最大化。”

About Zentek Ltd.

關於Zentek有限公司

Zentek is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection and treatment. Zentek is commercializing ZenGUARD™, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases. The Company also has an exclusive agreement to be the global exclusive commercializing partner for a newly developed, highly scalable, aptamer-based rapid pathogen detection technology.

Zentek是一家知識產權開發和商業化公司,專注於預防、檢測和治療領域的下一代醫療解決方案。Zentek正在將禪宗商業化警衞™是一種正在申請專利的塗料,具有99%的抗菌活性,包括對新冠肺炎的抗菌活性,並有可能將類似化合物用作治療傳染病的藥品。該公司還簽訂了一項獨家協議,將成為一項新開發的、高度可擴展的、基於適體的快速病原體檢測技術的全球獨家商業化合作夥伴。

For further information:

有關更多信息,請訪問:

Matt Blazei
Tel: (212) 655-0924
Email: mattb@coreir.com

馬特·布拉澤(Matt Blazei)
電話:(212)655-0924
電子郵件:mattb@coreir.com

To find out more about Zentek Ltd., please visit our website at . A copy of this news release and all material documents in respect of the Company may be obtained on ZEN's SEDAR profile at

欲瞭解更多有關Zentek Ltd.的信息,請訪問我們的網站:。本新聞稿的副本以及與本公司有關的所有重要文件可在Zen的SEDAR簡介中獲得,網址為:

Forward-Looking Statements

前瞻性陳述

This news release contains forward-looking statements. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Although Zentek believes that the assumptions and factors used in preparing the forward-looking information in this news release are reasonable, undue reliance should not be placed on such information, which only applies as of the date of this news release, and no assurance can be given that such events will occur in the disclosed time frames or at all. Zentek disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, other than as required by law.

本新聞稿包含前瞻性陳述。由於前瞻性陳述涉及未來的事件和條件,因此它們本身就包含固有的風險和不確定因素。儘管Zentek認為在準備本新聞稿中的前瞻性信息時使用的假設和因素是合理的,但不應過度依賴這些信息,因為這些信息只適用於本新聞稿發佈之日,不能保證此類事件將在披露的時間框架內發生或根本不會發生。除法律要求外,Zentek沒有任何更新或修改任何前瞻性信息的意圖或義務,無論是由於新信息、未來事件還是其他原因。

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所創業板交易所及其監管服務提供商(該術語在多倫多證券交易所創業板政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

SOURCE: Zentek Ltd.

資料來源:Zentek Ltd.


View source version on accesswire.com:
在accesswire.com上查看源代碼版本:

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論